BioNexus Gene Lab Operating Income 2019-2024 | BGLC

BioNexus Gene Lab operating income from 2019 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

BioNexus Gene Lab Operating Income 2019-2024 | BGLC

BioNexus Gene Lab operating income from 2019 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$125.1B
Cencora (COR)$45B
ICON (ICLR)$25B
DiDi Global (DIDIY)$19B
Avantor (AVTR)$18.4B
Natera (NTRA)$15.7B
Revvity (RVTY)$15.4B
Viatris (VTRS)$14.2B
CochLear (CHEOY)$12.8B
Solventum (SOLV)$12.5B
Medpace Holdings (MEDP)$11.2B
Charles River Laboratories (CRL)$10.6B
Sonic Healthcare (SKHHY)$8.8B
Doximity (DOCS)$7.4B
Bausch + Lomb (BLCO)$7B
HealthEquity (HQY)$6.8B
PACS (PACS)$6.2B
Organon (OGN)$5.1B
Life Times (LTH)$4.9B
Sotera Health (SHC)$4.7B
Surgery Partners (SGRY)$4.1B
Concentras Parent (CON)$3B
GoodRx Holdings (GDRX)$2.8B
BrightSpring Health Services (BTSG)$2.5B
Ardent Health Partners (ARDT)$2.4B
Progyny (PGNY)$2.2B
Alignment Healthcare (ALHC)$2.2B
Premier (PINC)$2.1B
Ryman Healthcare (RYHTY)$1.9B
AMN Healthcare Services Inc (AMN)$1.8B